Litheum

Quick links to important sections

Litheum

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Litheum

Quick Facts

  • Type: Mood stabilizer
  • Active Ingredient: Lithium (typically as lithium carbonate or citrate salts)
  • Primary Use: Treatment and maintenance for bipolar disorder (manic-depressive illness)

What is Litheum?

Litheum is the brand name for a medication containing lithium in its salt form, typically lithium carbonate or lithium citrate. It is classified as a mood stabilizer and is a cornerstone treatment in psychiatry. Lithium is a naturally occurring element that, when used therapeutically, works to decrease abnormal activity in the brain.

Primary Uses

Litheum is used for the treatment of manic episodes associated with bipolar disorder and for maintenance therapy to reduce the frequency and intensity of both manic and depressive episodes. It is considered effective in preventing recurrent mood episodes and is often regarded as a gold-standard treatment for its preventative properties.

Mechanism of Action

The precise way in which the lithium ion (Li^+) stabilizes mood is not fully understood, despite its long history of use. However, current research suggests it affects several processes within the central nervous system. This includes altering the transport of certain ions in nerve cells, modulating neurotransmitters like glutamate, and inhibiting key enzymes such as glycogen synthase kinase 3 (GSK-3) and inositol phosphatases. These actions collectively contribute to the drug's mood-regulating effects, helping to provide better control over emotions and reduce the severity of mood swings.

Litheum is taken orally and requires regular monitoring of blood levels due to its narrow therapeutic window—the difference between an effective dose and a toxic one.

What side effects are possible with Litheum?

Possible Side Effects and Safety Information

The safety profile of Litheum (lithium) is officially documented by regulatory authorities and centers on the need for continuous vigilance due to its narrow therapeutic window.

Official Adverse Reactions and Frequencies

Adverse reactions are classified by frequency based on official standards, such as those used by the European Medicines Agency (EMA):

Classification Examples of Documented Effects
Very Common (ge 1/10) Fine hand tremor, excessive thirst (polydipsia), and increased urination (polyuria).
Common (ge 1/100 to < 1/10) Nausea, vomiting, weight gain, changes in thyroid function (hypothyroidism), and specific ECG changes.

System-Specific and Chronic Safety Patterns

Adverse effects are grouped by system-organ class in regulatory texts, commonly involving the Nervous System, Renal and Urinary System, and Endocrine System. Effects such as tremor and nausea may be more noticeable at the start of treatment. Conversely, conditions like hypothyroidism and certain chronic renal changes, including Nephrogenic Diabetes Insipidus (NDI), are associated with prolonged exposure.

Serious Safety Considerations

The most critical risk is Lithium Toxicity, a severe neurological condition that can occur when serum lithium concentrations are elevated. This risk is compounded by conditions that lead to dehydration or sodium depletion, such as protracted sweating or severe diarrhea. Regulatory labels also document specific safety considerations for patient populations, noting that individuals with renal impairment and older adults require closer monitoring. Furthermore, use during pregnancy is associated with potential risks of fetal cardiac malformations.

Overdose and Emergency Response

Overdose Map: Overdose and when to seek help — official regulatory information for Litheum

Overdose scope

Documented overdose presentations: Lithium toxicity is closely related to serum lithium levels and can occur at concentrations near the therapeutic range. Symptoms are grouped by severity.

  • Mild to Moderate Manifestations: Include fine tremor, drowsiness, lightheadedness, lack of coordination (ataxia), blurred vision, slurred speech, and gastrointestinal symptoms such as nausea, vomiting, and diarrhea.
  • Severe Manifestations: Can include profound neurological signs such as convulsions, coma, severe hyperthermia, and persistent neurological sequelae. Cardiac changes and renal failure may also occur.

Dose-related or exposure-related factors: Toxicity is generally associated with serum concentrations ge 1.5 mEq/L, but may occur at lower levels in sensitive patients. Risk is increased by impaired renal function, dehydration, volume depletion, fever, and the use of certain other medications like diuretics or NSAIDs.

When to Seek Immediate Medical Help

Patients and caregivers must be aware of the signs of toxicity. Discontinue lithium therapy immediately and seek emergency medical assistance if any of the following signs of lithium toxicity occur: persistent diarrhea, vomiting, worsening tremor, significant ataxia (loss of coordination), severe drowsiness, or muscle weakness.

No specific antidote is known for lithium poisoning. Management focuses on discontinuing the medication, supportive care, and measures to enhance elimination, such as hydration or, in severe cases, hemodialysis.

Population-specific Overdose Notes

Elderly patients, those with significant cardiovascular or renal disease, or patients with sodium depletion are at a very high risk of developing lithium toxicity and require extreme caution.

Therapeutic Uses of Litheum

What Litheum Treats: Main Uses and Benefits

Litheum is commonly applied in clinical settings that involve acute or unstable symptom patterns, and is commonly used for managing conditions characterized by episodic or fluctuating manifestations, such as bipolar disorder. The medication is indicated for the treatment of acute mania and for long-term maintenance therapy to assist with managing the risk of recurrent episodes.

It helps address symptom clusters that may become intense or disruptive, such as heightened excitement, severe agitation, and impulsive behaviors during manic episodes. In situations where patients experience these challenging symptoms, Litheum may assist with maintaining functional stability and supports the patient during difficult episodes by easing distress.

“The continuous support provided by this therapy is relevant for easing symptoms associated with recurrent, episodic manic and depressive swings.”

Litheum is also considered relevant for its supportive therapeutic benefit as an augmentation strategy for persistent depressive features and in managing the risk associated with severe self-destructive intent. This supports its relevance across therapeutic domains where additional symptomatic support is needed.


Quick Fact: Relief for Dysregulated Mood Extremes

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Litheum — Official Regulatory Information

Litheum is an approved treatment for bipolar I disorder in adults and pediatric patients aged 7 years and older. However, its use is strictly limited by several patient health and clinical status conditions, which are defined in official government labeling.

Eligibility Classification Population / Condition
Populations for Use Adults and children 7 years and older. (Extended-release forms are generally restricted to patients 12 years and older).
Contraindicated Patients with severe renal disease or insufficiency. Patients with significant/severe cardiovascular disease, severe debilitation, dehydration, or sodium depletion. Use is also prohibited in patients taking diuretics and in those with known hypersensitivity to the drug.
Restrictions/Not Recommended Children 7 years or younger (safety/efficacy not established). Patients with Brugada Syndrome or a family history of the condition. Patients with untreated hypothyroidism. Older adults require caution and close monitoring, often needing lower doses.
Pregnancy/Lactation Status Use during pregnancy may cause fetal harm and requires risk assessment; withdrawal for the first trimester is often advised. Use during lactation is generally not recommended/contraindicated due to the drug being excreted in human milk.

All eligibility rules are based on governmental regulatory documents that establish which patient populations can safely receive this medicine, focusing on conditions that drastically increase the risk of toxicity.

What should I know about interactions with other medicines?

Interaction Map: Interactions with other medicines and products — official regulatory information for Litheum

Interaction Scope

Category Official Regulatory Documentation
Medicinal product categories with documented interactions: Diuretics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), Renin-Angiotensin System Antagonists, Serotonergic Agents (e.g., SSRIs, MAOIs), Antipsychotics / Neuroleptics, Neuromuscular Blocking Agents.
Mechanistic basis of interactions (only if stated in label): Altered renal clearance (pharmacokinetic effect due to fluid and electrolyte changes), Additive neurological effects (pharmacodynamic), Additive serotonergic effects (pharmacodynamic).
Population-specific interaction notes (if applicable): Extreme caution is required for patients with impaired renal function, as their compromised excretion capacity heightens all exposure-related interaction risks.
Interaction-related restrictions: Contraindicated in conditions with high toxicity risk, such as severe renal disease, cardiovascular insufficiency, or sodium depletion. The regulatory documentation also restricts low-salt diets due to the risk of increasing Litheum serum levels.

Interaction Classifications (High-Level)

Classification Official Regulatory Documentation
Interaction severity classification (as defined in official documents): Contraindicated (combination with severe renal impairment); Serious/Life-Threatening Risk (Serotonin Syndrome, Encephalopathic Syndrome risk); Clinically Significant (exposure modification).
Interaction-context constraints (as defined in official documents): Maintaining a normal, consistent salt and fluid intake is required. Close monitoring of serum Litheum levels is mandatory when co-administering agents known to affect renal clearance or neurotoxicity.

Resulting Interaction Structure

Official interaction statements:

  • Co-administration of Litheum and diuretics or NSAIDs is documented to increase plasma Litheum concentrations and heighten the risk of toxicity by affecting renal clearance.
  • The risk of Serotonin Syndrome is formally increased when Litheum is combined with other serotonergic agents, including the herbal product St. John's Wort.
  • Concurrent use with Neuroleptics has been associated with a specific risk of encephalopathic syndrome and other neurological adverse reactions.
  • Xanthine preparations (e.g., Caffeine, Theophylline) and Alkalinizing Agents are documented as substances that may decrease Litheum concentrations, potentially risking loss of intended effect.

Connection to the overall interaction profile (2–4 sentences): Regulatory documents define Litheum's interaction structure primarily through two pathways: pharmacokinetic interactions that severely modify plasma exposure due to altered renal clearance, and pharmacodynamic interactions that result in additive central nervous system effects. This framework results in explicit restrictions against combining Litheum with conditions or substances that compromise renal function and formal warnings regarding the synergistic risk of adverse neurological events.

Mechanism of Action

How Litheum Works

The action of the lithium ion ( Li^+) is characterized by a multi-target engagement, primarily within the central nervous system (CNS). Its effects arise from the simultaneous modulation of two key domains: intracellular enzyme activity and neuronal ion dynamics, which collectively alters the characteristics of signaling.


Molecular Modulation of Signaling Enzymes

Litheum functions as an enzyme modulator by directly inhibiting key regulatory proteins: Glycogen Synthase Kinase 3 ( GSK-3) and Inositol Monophosphatase ( IMPase). By disrupting the activity of IMPase, the drug functionally reduces the pool of signaling molecules in the phosphatidylinositol pathway, a mechanism critical for limiting the intensity and frequency of neuronal firing. Simultaneously, GSK-3 inhibition triggers a neuroplasticity cascade, leading to the enhanced transcription of neuroprotective factors like BDNF. This slow-acting cascade is responsible for the promotion of neuroprotection and structural changes within neural circuits.


Altering Neuronal Ion Balance

The lithium ion ( Li^+) physically competes with other metal cations, notably sodium ( Na^+), for sites on transporters and channels within the nerve cell membrane. This ion competition alters the normal flow of Na^+ across the membrane, which is a fundamental biophysical process governing electrical signal transmission. The resulting interference limits the neuron's ability to fire at high frequencies, thereby limiting high-frequency signal propagation across the network and modulating biophysical properties that govern central neural network output.

Dosage and Administration Information

How to use Litheum

The usage of Litheum (lithium salts) is governed by strict protocols, with the dosage precisely tailored to serum concentration, not fixed weight. The administration principles focus on the oral route and require intensive monitoring to ensure levels remain within the narrow therapeutic range.


Administration Guidelines

Guideline Area Instructions
Route of Administration Exclusively oral (by mouth) for all approved tablet, capsule, and solution formulations.
Standard Dosing Goal Doses are adjusted to maintain specific serum lithium concentrations; 0.8 to 1.2 mEq/L for acute treatment, and typically 0.6 to 1.0 mEq/L for maintenance.
Frequency and Timing Immediate-release forms are often taken in divided doses (two or three times daily); extended-release forms are typically dosed once or twice daily. Doses should be taken at the same time(s) each day.
Contextual Intake The medication should be taken with or immediately after food to help reduce potential stomach irritation. Adequate and consistent intake of fluids and salt must be maintained throughout therapy.
Special Handling Extended-release tablets must be swallowed whole and must never be crushed, broken, or chewed, as this destroys the controlled-release mechanism.
Population Adjustments Treatment is generally initiated at lower doses and titrated slowly for older adults and individuals with impaired kidney function.

Procedural Structure

The required administration protocol mandates a sequence of actions designed to manage systemic levels:

  • Dose Initiation and Titration: Begin with a starting dose, which is followed by a period of upward adjustment based on laboratory measurements.
  • Serum Monitoring: Blood samples for determining the lithium concentration must be drawn at specified intervals (e.g., 8 to 12 hours after the previous dose) and regularly throughout therapy.
  • Long-term Maintenance: Once stabilization is achieved, the regimen transitions to a long-term maintenance dose guided by the lower target serum range.

Recent Clinical Evidence

Research evidence / Overview of studies for Litheum

Evidence for Use in Long-Term Mood Stability (Maintenance)

Research has extensively evaluated Litheum in conditions characterized by fluctuating or episodic manifestations of mood. This high-level research includes many controlled trials where adults with Bipolar Disorder were observed in studies lasting one to four years. These studies primarily monitored outcomes reflecting daily functioning and focused on time to relapse—the duration before a new manic, depressive, or mixed episode occurred. Reports from these studies describe patterns where a longer period before a manic episode recurred was observed in the populations taking Litheum compared to the populations not receiving Litheum. However, when research examined the outcomes for preventing depressive episodes, the findings were mixed, suggesting less consistent patterns across studies.

Evidence for Use in Acute Mania

Litheum was studied for its use in research exploring short-term symptom changes during conditions involving periods of heightened symptoms. The clinical research consists mainly of short-term Randomized Controlled Trials that last only a few weeks. The primary outcomes monitored the change in symptom severity scores (measured by validated scales for mania) and the proportion of participants who met criteria for achieving response or remission. Comparative evidence is lacking for direct head-to-head research against all currently available treatments for acute mania.

Evidence for Support Against Self-Destructive Intent

An important area of research that Litheum was evaluated in concerns outcomes related to suicidal acts and attempts. Because these are rare events, research depends heavily on Systematic Reviews and large-scale Longitudinal Observational Studies. The aggregated data show patterns related to suicide or attempted suicide observed in the populations receiving Litheum compared to populations not receiving Litheum. Reports suggest a similar pattern across different diagnostic groups in the observed high-risk populations. Certainty remains low in some settings because the interpretation relies significantly on evidence derived from settings with varying symptom burdens (observational data).

Key Studies & References

  1. Bipolar disorder: assessment and management (NICE Guideline NG185)
  2. Long-term effect of lithium maintenance treatment on recurrence in bipolar disorder: a systematic review and meta-analysis

Frequently Asked Questions (FAQ)

Common questions about Litheum (FAQ)


Q: Does Litheum cause weight changes?

A: Regulatory documents state that weight gain is a common documented effect associated with the use of Litheum. This information is classified based on frequency data gathered from clinical studies and patient surveillance.


Q: What foods or drinks should people using Litheum avoid?

A: Official medication information emphasizes maintaining a consistent intake of fluids and salt. Official documents restrict low-salt diets because this can affect the level of the drug in the body. Some health authorities also advise patients to limit excessive caffeine intake.


Q: Is it true that Litheum can affect sleep?

A: According to the official product information, drowsiness is listed as a potential adverse reaction. This reaction is consistent with the drug's effect on alertness.


Q: Do I need to get blood tests while using Litheum?

A: Official administration protocols include requirements for regular serum monitoring, which involves blood tests. This is necessary to ensure the drug's concentration stays within the therapeutic range and to check for potential changes in kidney and thyroid function.


Q: Does Litheum interact with common supplements like St. John's Wort?

A: Official documents caution that the herbal product St. John's Wort is classified as a serotonergic agent. Combining it with Litheum is documented to increase the risk of an adverse event known as Serotonin Syndrome.


Q: Are there any specific warnings about driving or operating machinery while on Litheum?

A: Official information advises avoiding driving or operating dangerous machinery until an individual understands how the drug may affect their alertness and coordination. This warning is due to the potential for the medication to cause drowsiness.


Q: How long does Litheum stay in your system after stopping?

A: Based on pharmacokinetic data, the time required for the body to eliminate half of the drug (known as the half-life) is documented to be approximately 18 to 36 hours.


Q: Can Litheum cause headaches?

A: Official drug information lists headache as a documented adverse reaction. It is typically described as a miscellaneous effect that may occur and is generally not related to the specific dosage being used.


Q: Is Litheum available in different forms (e.g., tablet, liquid)?

A: Yes. Official documents confirm that the drug is available in multiple forms for oral administration. These typically include immediate-release tablets, extended-release tablets, capsules, and liquid solutions.


Q: What are the typical expected benefits described in research for Litheum?

A: Research studies have evaluated the drug for its ability to increase the time before a mood episode recurs (time to relapse) and for its use in reducing the severity of acute manic symptoms. These are the core outcomes described in the evidence summaries.


Q: What is the purpose of the 'inactive ingredients' listed in Litheum?

A: Inactive ingredients are components added to the medication for purposes other than the therapeutic effect. They are typically used to provide the structure, stability, and color of the product, or to control the rate at which the active ingredient is released into the body.


Q: Does Litheum affect blood pressure readings?

A: Official safety information lists potential ECG changes (effects on heart electrical activity) as a common side effect. Furthermore, regulatory documents note that co-administration with certain blood pressure medicines can increase the risk of toxicity.


Q: Does Litheum interact with cannabis or CBD products?

A: Regulatory-aligned resources suggest that co-administration with cannabidiol (CBD) may increase the risk of certain central nervous system side effects, such as drowsiness. Close monitoring is often required when these are used concurrently due to potential effects on the drug concentration.


Q: Is it normal to feel dizzy or lightheaded when first starting Litheum?

A: Official documents list dizziness and lightheadedness as potential adverse reactions. These effects are particularly noted when the concentration of the medication in the blood is at the higher end of the therapeutic range.


Q: Why are children sometimes not allowed to use Litheum?

A: Use is restricted in children seven years of age and younger because regulatory authorities have determined that the safety and efficacy have not been established in this specific age group.


Q: What does the term 'off-label use' mean regarding Litheum?

A: The term 'off-label use' is a regulatory concept that refers to when a licensed medication is prescribed for a purpose, dosage, or patient population that is not specifically listed and approved on the official regulatory label.


Q: Is Litheum a generic drug or is it only available as a brand name?

A: Litheum is a brand name for the medication. However, the active ingredient is also widely available in the generic form, which is typically labeled as lithium carbonate or lithium citrate.


Q: How is Litheum different from generic versions?

A: Generic versions contain the same active ingredient and are required to meet the same quality and performance standards as the brand name product. The primary differences lie in the inactive ingredients used in the formulation, which may vary.


Q: How long does it typically take for Litheum to start working?

A: The drug’s mechanism involves a slow-acting cascade that promotes structural changes in the brain over time. While it is started for acute symptoms, normalization of those symptoms may take one to three weeks in some patients.


Q: Is Litheum a long-term treatment or short-term?

A: The medication is approved for two distinct purposes: the short-term treatment of acute manic episodes and for long-term maintenance therapy. The long-term use is intended to reduce the frequency and intensity of mood episodes.


Q: Can Litheum be taken with over-the-counter pain relievers like ibuprofen?

A: Official documents list Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) as a category of medicine that is documented to increase Litheum concentrations. This category includes common pain relievers like ibuprofen, and co-administration may require adjustment or monitoring.


Q: What are the signs of an allergic reaction to Litheum?

A: Official safety information includes warnings for hypersensitivity and describes signs of a serious allergic reaction. These may include swelling of the lips, tongue, or throat, difficulty breathing, or certain skin changes.


Q: What is the risk of having a serious side effect from Litheum?

A: Regulatory documents state that the most critical risk is Lithium Toxicity, a severe condition that can occur if concentrations in the blood become too high. The drug is officially described as having a narrow therapeutic window, meaning careful monitoring is required to keep levels in the effective range.


Q: Does the dose of Litheum need to be adjusted based on age or weight?

A: Dose adjustments and close monitoring are described in official guidelines for specific populations, including older adults and individuals with impaired kidney function. Some official guidelines for younger pediatric patients may also include weight-based dosing recommendations.


Q: Is it common for Litheum to be used alongside other prescription medicines?

A: Official regulatory information includes an extensive section documenting its interactions with numerous other medicines. The existence of this detailed interaction map implies that co-administration is expected, and close monitoring is often required when Litheum is used with other prescription medicines.


Q: Is the long-term safety of Litheum well-studied?

A: The long-term safety profile is continually monitored through ongoing surveillance and research, including large longitudinal observational studies. Regulatory documents specifically list potential chronic changes associated with prolonged exposure, such as effects on the kidney and thyroid gland.

How should Litheum be stored and disposed of?

How to Store and Dispose of Litheum

The storage and disposal of Litheum (lithium) must strictly follow officially documented regulatory requirements to ensure product quality and safety.


Required Storage Conditions

Litheum must be stored at Controlled Room Temperature (CRT), typically between 20 C and 25 C (68 F and 77 F). The medication must be protected from moisture and kept from freezing. It is required to keep the product in its tightly closed container to maintain stability.

Safety and Disposal

As a crucial safety measure, Litheum must be stored out of the reach of children. Unused or expired medication must be handled and disposed of according to local regulations and the instructions provided by a healthcare professional.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Litheum found in:

A-Z Index: